Spots Global Cancer Trial Database for small cell lung carcinoma
Every month we try and update this database with for small cell lung carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | NCT02062632 | Esophageal Carc... Hypopharyngeal ... Laryngeal Carci... Lymphoma Mesothelioma Metastatic Mali... Metastatic Mali... Metastatic Mali... Non-Small Cell ... Sarcoma Small Cell Lung... Thymic Carcinom... Thymoma Thyroid Gland C... | Doxepin Hydroch... Placebo Quality-of-Life... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Molecular Analysis and Treatment Options of SCLC | NCT05945745 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | Chemotherapy | 18 Years - | Shanghai Chest Hospital | |
| Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study | NCT05873790 | Lung Cancer | Serplulimab plu... | 18 Years - 75 Years | The First Hospital of Jilin University | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | NCT03532880 | Small-cell Lung... Small Cell Lung... | Olaparib Pill 5... Olaparib Pill 1... Olaparib Pill 1... Olaparib Pill 2... Olaparib Pill 2... Olaparib Pill 3... Radiotherapy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. | NCT04358237 | Small Cell Lung... | Lurbinectedin Pembrolizumab | 18 Years - | Blanco, Dr Antonio Calles MD | |
| A Mobile Supportive Care App for Patients With Metastatic Lung Cancer | NCT03512015 | Nonsmall Cell L... Small Cell Lung... | The Lung Cancer... Standard care | 18 Years - | Bocconi University | |
| A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. | NCT05683977 | Small Cell Lung... | durvalumab | - | AstraZeneca | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | NCT03994744 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | PD-1 inhibitor Metformin | 18 Years - 65 Years | Hunan Cancer Hospital | |
| Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer | NCT00658580 | Small Cell Lung... | Cisplatin + eto... Epirubicin + if... | 18 Years - | European Lung Cancer Working Party | |
| LBH Phase II in Small Cell Lung Cancer (SCLC) | NCT01222936 | Small Cell Lung... | LBH581 | 18 Years - 75 Years | Southern Europe New Drug Organization | |
| Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer | NCT04901754 | Small Cell Lung... | Camrelizumab Pl... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer | NCT02394548 | Non-small Cell ... Small Cell Lung... | Contralateral E... | 18 Years - | Massachusetts General Hospital | |
| PET-guided Radiotherapy for Patients With Small Cell Lung Cancer. | NCT06247163 | Small Cell Lung... | PET based Radit... | 18 Years - | University Hospital, Essen | |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers | NCT05582031 | Anal Squamous C... Colorectal Neop... Soft Tissue Sar... Malignant Pleur... Small Cell Lung... Castrate Resist... Neuroendocrine ... Gastroenteropan... | Regorafenib in ... | 18 Years - | Translational Research in Oncology | |
| A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | NCT00445198 | Small Cell Lung... Small Cell Lung... | ABT-263 | 18 Years - | AbbVie | |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | NCT05882058 | Small Cell Lung... Neuroendocrine ... | BI 764532, form... BI 764532, form... | 18 Years - | Boehringer Ingelheim | |
| Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | NCT01450761 | Small Cell Lung... | Ipilimumab Placebo matchin... Etoposide Cisplatin Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | NCT03850067 | Small Cell Lung... | CC-90011 Cisplatin Carboplatin Etoposide Nivolumab | 18 Years - | Celgene | |
| Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | NCT04620837 | Small Cell Lung... | Tislelizumab Anlotinib hydro... | 18 Years - 75 Years | ChineseAMS | |
| A Study of AK-01 (LY3295668) in Solid Tumors | NCT03092934 | Neoplasms Neoplasm Metast... Triple Negative... Head and Neck N... Breast Neoplasm... Solid Tumor, Ad... Small Cell Lung... | LY3295668 | 18 Years - | Eli Lilly and Company | |
| Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | NCT03319940 | Small Cell Lung... | Tarlatamab Pembrolizumab CRS Mitigation ... | 18 Years - | Amgen | |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | NCT04902872 | Solid Tumor, Ad... Epithelial Ovar... Small Cell Lung... Breast Cancer Colorectal Canc... Pancreas Cancer Appendix Cancer Non-small Cell ... Gastric Cancer Esophagus Cance... Urothelial Carc... Sarcoma | CBX-12 | 18 Years - | Cybrexa Therapeutics | |
| Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | NCT03319940 | Small Cell Lung... | Tarlatamab Pembrolizumab CRS Mitigation ... | 18 Years - | Amgen | |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NCT05297734 | End of Life Cancer | Receive technol... Receive redesig... | 21 Years - | Stanford University | |
| Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | NCT04665856 | Small Cell Lung... | Tiragolumab Atezolizumab Carboplatin Etoposide Tiragolumab Mat... | 18 Years - | Hoffmann-La Roche | |
| Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | NCT04507919 | Small Cell Lung... | Dabrafenib Trametininb | 18 Years - 99 Years | Novartis | |
| Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) | NCT06419179 | Small Cell Lung... | Durvalumab Olaparib | 18 Years - 120 Years | University of Cologne | |
| Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China | NCT01928836 | Lung Neoplasms | 40 Years - 75 Years | Chinese Alliance Against Lung Cancer | ||
| Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | NCT01441349 | Small Cell Lung... | IP chemotherapy IP chemotherapy... | 18 Years - | National Cancer Center, Korea | |
| Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer | NCT03568097 | Small Cell Lung... | Avelumab | 18 Years - | Hellenic Cooperative Oncology Group | |
| Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) | NCT05049863 | Small-cell Lung... Small Cell Lung... | Mycophenolate M... Allopurinol Irinotecan | 18 Years - | Washington University School of Medicine | |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | NCT05882058 | Small Cell Lung... Neuroendocrine ... | BI 764532, form... BI 764532, form... | 18 Years - | Boehringer Ingelheim | |
| A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | NCT00926640 | Carcinoma Neuro... Small Cell Lung... Malignant Epith... | Belinostat Cisplatin Etoposide | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer | NCT04901754 | Small Cell Lung... | Camrelizumab Pl... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer | NCT01540045 | Non-Small Cell ... Dysgeusia Taste Disorders Lung Neoplasms Small Cell Lung... | 18 Years - 90 Years | Instituto Nacional de Cancerologia de Mexico | ||
| Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China | NCT01928836 | Lung Neoplasms | 40 Years - 75 Years | Chinese Alliance Against Lung Cancer | ||
| Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | NCT01441349 | Small Cell Lung... | IP chemotherapy IP chemotherapy... | 18 Years - | National Cancer Center, Korea | |
| Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study | NCT05873790 | Lung Cancer | Serplulimab plu... | 18 Years - 75 Years | The First Hospital of Jilin University | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer | NCT00977561 | Small Cell Lung... | figitumumab Cisplatin (Or C... Etoposide Cisplatin (Or C... Etoposide | 18 Years - | Pfizer | |
| A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | NCT03850067 | Small Cell Lung... | CC-90011 Cisplatin Carboplatin Etoposide Nivolumab | 18 Years - | Celgene | |
| PEN-866 in Patients With Advanced Solid Malignancies | NCT03221400 | Carcinoma Endometrial Ade... Neoplasms Squamous Cell C... Adenocarcinoma ... Advanced Cancer Solid Tumor Solid Carcinoma Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Gastric Cancer Gastric Adenoca... Gastroesophagea... Small-cell Lung... Small Cell Lung... Pancreatic Duct... Pancreatic Aden... | PEN-866 Sodium fluorouracil Folinic acid Niraparib | 18 Years - | Tarveda Therapeutics | |
| A Study of LY2940680 in Small Cell Lung Cancer | NCT01722292 | Small Cell Lung... | LY2940680 Carboplatin Etoposide Placebo | 18 Years - | Eli Lilly and Company | |
| Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer | NCT02041845 | Small Cell Lung... | 45 Gy in 30 fra... 60 Gy in 40 fra... | 18 Years - | Norwegian University of Science and Technology | |
| LBH Phase II in Small Cell Lung Cancer (SCLC) | NCT01222936 | Small Cell Lung... | LBH581 | 18 Years - 75 Years | Southern Europe New Drug Organization | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | NCT00926640 | Carcinoma Neuro... Small Cell Lung... Malignant Epith... | Belinostat Cisplatin Etoposide | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer | NCT01357395 | Small Cell Lung... | Amuvatinib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | NCT05329623 | Small Cell Lung... | JDQ443 | 18 Years - 75 Years | Novartis | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer) | NCT01573338 | Small Cell Lung... | Roniciclib (BAY... Etoposide Cisplatin Carboplatin | 18 Years - | Bayer | |
| A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer | NCT01357395 | Small Cell Lung... | Amuvatinib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | NCT03232593 | Urothelial Carc... Carcinoma, Non-... Small Cell Lung... Triple Negative... Hepatocellular ... | Atezolizumab | - | Hoffmann-La Roche | |
| A Phase IIII Study of AL8326 in Small Cell Lung Cancer | NCT06247605 | Small Cell Lung... | AL8326 tablets placebo | 18 Years - | Advenchen Laboratories, LLC | |
| Biology of Young Lung Cancer Study: The YOUNG LUNG Study | NCT05265429 | Non Small Cell ... Small Cell Lung... | Data and Specim... | 15 Years - 45 Years | Dana-Farber Cancer Institute | |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | NCT03994744 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | PD-1 inhibitor Metformin | 18 Years - 65 Years | Hunan Cancer Hospital | |
| Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | NCT05450965 | Small-cell Lung... Small Cell Lung... | Onvansertib | 18 Years - | University of Maryland, Baltimore | |
| A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | NCT02874664 | Small Cell Lung... | Rovalpituzumab ... | 18 Years - | Stemcentrx | |
| A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | NCT05419076 | Lung Cancer Lung Cancer Met... Brain Metastase... Brain Metastase... Small-cell Lung... Small Cell Lung... | Stereotactic Ra... Cerebrospinal f... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer | NCT00927875 | Small Cell Lung... | BMS-833923 Carboplatin Etoposide | 18 Years - | Bristol-Myers Squibb | |
| Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer | NCT00658580 | Small Cell Lung... | Cisplatin + eto... Epirubicin + if... | 18 Years - | European Lung Cancer Working Party | |
| Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL) | NCT02397733 | Small Cell Lung... | Prophylactic cr... Hippocampal avo... | 18 Years - | Grupo de Investigación Clínica en Oncología Radioterapia | |
| FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction | NCT05703997 | Small Cell Lung... | Cyclic, 5-day c... Atezolizumab | 18 Years - 75 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | NCT04453930 | Small Cell Lung... | Camrelizumab，an... Platinum Irinotecan Apatinib | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer | NCT01187615 | Small Cell Lung... | Regorafenib (BA... Regorafenib (BA... | 18 Years - | Bayer | |
| Oral Green Tea Extract for Small Cell Lung Cancer | NCT01317953 | Small Cell Lung... | epigallocatechi... | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer | NCT01540045 | Non-Small Cell ... Dysgeusia Taste Disorders Lung Neoplasms Small Cell Lung... | 18 Years - 90 Years | Instituto Nacional de Cancerologia de Mexico | ||
| Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | NCT04996771 | Small Cell Lung... | Surufatinib,Eto... Surufatinib,Eto... | 18 Years - 80 Years | Sun Yat-sen University | |
| A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer | NCT00927875 | Small Cell Lung... | BMS-833923 Carboplatin Etoposide | 18 Years - | Bristol-Myers Squibb | |
| Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | NCT02034123 | Carcinoma, Smal... | GSK2879552 | 18 Years - | GlaxoSmithKline | |
| Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer | NCT02772107 | Extensive-stage... | Temozolomide first-line chem... Prophylactic cr... thoracic radiot... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Biology of Young Lung Cancer Study: The YOUNG LUNG Study | NCT05265429 | Non Small Cell ... Small Cell Lung... | Data and Specim... | 15 Years - 45 Years | Dana-Farber Cancer Institute | |
| A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer | NCT03639194 | Small Cell Lung... | ABBV-011 Budigalimab | 18 Years - | AbbVie | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | NCT01941316 | Small Cell Lung... Non Small Cell ... Irinotecan Sens... | Carfilzomib Irinotecan | 18 Years - | Cancer Research and Biostatistics Clinical Trials Consortium |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
